94160-98-2 Usage
Explanation
The compound consists of 9 carbon atoms, 17 hydrogen atoms, 1 nitrogen atom, 2 oxygen atoms, and a hydrochloride ion (HCl).
2. Bicyclic compound derivative
Explanation
The structure of the compound is derived from a bicyclic ring system, which is a closed loop of atoms that forms two interconnected rings.
3. R-configuration
Explanation
The compound has a specific three-dimensional arrangement of its atoms, with the R-configuration indicating the orientation of the substituents around the central carbon atom.
4. Building block in pharmaceutical synthesis
Explanation
The compound is commonly used as an intermediate or starting material in the synthesis of various pharmaceutical drugs and chemical intermediates, due to its versatile structure and reactivity.
5. Production of neurotransmitters
Explanation
The compound has potential applications in the production of certain neurotransmitters, which are essential for the proper functioning of the nervous system.
6. Medicinal and pharmaceutical chemistry applications
7. Hydrochloride salt form
Explanation
The presence of the hydrochloride ion (HCl) in the compound makes it more stable and suitable for various chemical reactions and applications, as it can easily form salts with other compounds and facilitate their solubility.
Check Digit Verification of cas no
The CAS Registry Mumber 94160-98-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,4,1,6 and 0 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 94160-98:
(7*9)+(6*4)+(5*1)+(4*6)+(3*0)+(2*9)+(1*8)=142
142 % 10 = 2
So 94160-98-2 is a valid CAS Registry Number.
94160-98-2Relevant articles and documents
Discovery of a Novel, Highly Potent, and Selective Thieno[3,2- d]pyrimidinone-Based Cdc7 Inhibitor with a Quinuclidine Moiety (TAK-931) as an Orally Active Investigational Antitumor Agent
Kurasawa, Osamu,Miyazaki, Tohru,Homma, Misaki,Oguro, Yuya,Imada, Takashi,Uchiyama, Noriko,Iwai, Kenichi,Yamamoto, Yukiko,Ohori, Momoko,Hara, Hideto,Sugimoto, Hiroshi,Iwata, Kentaro,Skene, Robert,Hoffman, Isaac,Ohashi, Akihiro,Nomura, Toshiyuki,Cho, Nobuo
, p. 1084 - 1104 (2020/02/05)
In our pursuit of developing a novel, potent, and selective cell division cycle 7 (Cdc7) inhibitor, we optimized the previously reported thieno[3,2-d]pyrimidinone analogue I showing time-dependent Cdc7 kinase inhibition and slow dissociation kinetics. These medicinal chemistry efforts led to the identification of compound 3d, which exhibited potent cellular activity, excellent kinase selectivity, and antitumor efficacy in a COLO205 xenograft mouse model. However, the issue of formaldehyde adduct formation emerged during a detailed study of 3d, which was deemed an obstacle to further development. A structure-based approach to circumvent the adduct formation culminated in the discovery of compound 11b (TAK-931) possessing a quinuclidine moiety as a preclinical candidate. In this paper, the design, synthesis, and biological evaluation of this series of compounds will be presented.
